Inhibiting monoacylglycerol lipase (magl)
AssigneePsy Therapeutics, Inc.
InventorJacob Matthew Hooker
Life of this patent
Estimating the term…
Abstract
Provided herein are 1H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl methanone compounds substituted with aryl and pyrazolyl moieties, further substituted, for inhibiting monoacylglycerol lipase (MAGL), utilized in the treatment of a MAGL-mediated disease or disorder i.e., neurodegenerative diseases, pain, and inflammatory diseases or conditions, as well as cancer, and related methods of making and using the compounds.
Claims9
-43. (canceled)
-62. (canceled)
A method of reversibly inhibiting monoacylglycerol lipase (MAGL) in a human subject in need thereof, comprising the step of administering to the human subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
- (2,4-difluoro-5-hydroxyphenyl){6-[3-methyl-1-(o-tolyl)-5-pyrazolyl]-2-aza-2-spiro[3.3]heptyl}methanone;
- 4-hydroxy-2-({6-[3-methyl-1-(o-tolyl)-5-pyrazolyl]-2-aza-2-spiro[3.3]heptyl}carbonyl)benzonitrile:
- (2-fluoro-5-hydroxyphenyl){6-[1-(5-fluoro-2-tolyl)-3-methyl-5-pyrazolyl]-2-aza-2-spiro[3.3]heptyl}methanone;
- (2-fluoro-5-hydroxyphenyl)(6-{3-methyl-1-[o-(trifluoromethyl)phenyl]-5-pyrazolyl}-2-aza-2-spiro[3.3]heptyl)methanone:
- (2-ethoxy-4-fluorophenyl){6-[3-methyl-1-(o-tolyl)-5-pyrazolyl]-2-aza-2-spiro[3.3]heptyl}methanone;
- and
- [4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]{6-[3-methyl-1-(o-tolyl)-5-pyrazolyl]-2-aza-2-spiro[3.3]heptyl}methanone,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.